Seven criteria, each scored 0 to 100 on a published scale, weighted into one number.
Weak. ACADIA Pharmaceuticals Inc. scores higher than 15% of the 2,231 companies Ryufin scores.
Held back by valuation and return on capital, with nothing carrying it far.
Healthcare median 19 · all companies 55
The biggest move was up 7 points from 2021 to 2022, mostly capital allocation.
26% of the score, 33% here after data gaps
ACADIA Pharmaceuticals Inc. is valued at 39.3x its operating profit, including debt: a very rich multiple.
18% of the score, 23% here after data gaps
Over 7 years the business earned -135% a year after tax on the capital it uses.
16% of the score, 20% here after data gaps
No operating profit over the period, so nothing was earned to reinvest.
14% of the score, 18% here after data gaps
How management spends the money: shares bought back or issued, and whether assets grow faster than the business they serve.
Taken out: its 12% is shared by the others
Margins have been too thin to measure a cycle against.
Taken out: its 8% is shared by the others
No debt or interest figures on file.
6% of the score, 8% here after data gaps
Whether the reported profit arrives as cash, and whether the accounts show the usual signs of stretching.
Each criterion earns 0 to 100 points on the scale drawn under it, and the RyuScore is their average weighted 26, 18, 16, 14, 12, 8 and 6. Scales bend in the company's favour between their ends, so an ordinary figure is never already near zero. For ACAD, cycle position and balance sheet could not be measured from the filings, so they are taken out and the remaining weights scale up.
Built from the company's annual and quarterly filings with the SEC and today's share price. Banks, insurers and property trusts are not scored: their debt is their raw material, so these yardsticks mean something else there. Figures as of 2026-06-30, latest annual report FY2025.